GENE ONLINE|News &
Opinion
Blog

2021-09-01| Asia-Pacific

Daiichi Sankyo Partners with Lilly on a Second Migraine Drug Deal in Japan

by Tyler Chen
Share To

Japan’s Daiichi Sankyo has struck another migraine drug deal with Eli Lilly’s Japan subsidiary to commercialize a first-in-class 5-HT1F receptor agonist for migraine called lasmiditan succinate. The drug was approved by the USFDA in October 2019, and Lilly has already filed a new drug application in Japan.

Migraine is a neurological disease that causes 4 to 72 hours of headache in one or both sides of the head. It usually comes with symptoms like nausea and vomiting. Currently, migraines have no cure, but symptoms can be addressed with treatments.

 

First and Only FDA-Approved 5-HT1F Receptor Agonist

Lasmiditan succinate binds to 5-HT1F receptors on trigeminal nerve cells, thereby inhibiting pain transmission and the overactivity of trigeminal nerve cells which plays a part in causing migraines. It is also the first new class of acute migraine treatment approved by the USFDA in over 20 years.

As per the term, Lilly will be responsible for the authorization of lasmiditan succinate while Daiichi Sankyo will take care of distribution and sales after the drug is approved in Japan.

In October 2020, Daiichi Sankyo partnered up with Lilly on their first migraine drug deal to commercialize an antibody called Emgality (galcanezumab). The antibody can bind to a relevant target called calcitonin gene-related peptide (CGRP) to treat migraines. Emgality was approved in Japan within a year, becoming the country’s first approved antibody as the preventive treatment for migraines.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Eli Lilly and BI Notch Clinical Win for Kidney Disease Drug
2022-11-07
M&A
Eli Lilly Snatches Up Akouos Treating Ear Conditions for $487 million
2022-10-18
Novartis Ordered to Pay $177.8 million to Plexxikon for Patent Infringements
2022-10-03
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!